PF4 and COVID-19: This is supported by the observations that COVID-19 and HIT share many clinical similarities; COVID-19 patients are often exposed to heparin in the context of hospitalization; and a high proportion of COVID-19 patients test positive for anti-PF4/heparin antibodies on further testing (60, 61).